Myelodysplastic Syndrome Clinical Trial
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in Treating Patients With Myelodysplastic Syndromes
Summary
RATIONALE: Photopheresis treats the patient's blood with drugs and ultraviolet light outside the body and kills the white blood cells. Giving photopheresis, pentostatin, and radiation therapy before a donor bone marrow or stem cell transplant helps stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving pentostatin before transplant and cyclosporine or mycophenolate mofetil after transplant may stop this from happening.
PURPOSE: This phase II trial is studying how well giving pentostatin together with photopheresis and total-body irradiation work before donor bone marrow transplant in treating patients with myelodysplastic syndromes.
Full Description
OBJECTIVES:
Determine the complete response rate in patients with myelodysplastic syndromes treated with reduced-intensity allogeneic bone marrow transplantation, including photopheresis, total body irradiation, and pentostatin.
Determine the disease-free and overall survival of patients treated with this regimen.
Determine the engraftment rate of donor cells in patients treated with this regimen.
Determine the extent and duration of acute and chronic graft-versus-host disease in patients treated with this regimen.
Determine the toxicity of this regimen in these patients.
OUTLINE: This is a single-arm, two-stage, multicenter phase II study.
Preparative Regimen: Patients undergo photopheresis using methoxsalen on days -7 and -6 and receive pentostatin intravenously (IV )continuously on days -5 and -4. Total body irradiation is administered on days -3 and -2 for a total of 3 doses.
Transplantation: Allogeneic bone marrow or peripheral blood stem cells are infused on day 0.
Acute graft-vs-host-disease (GVHD) prophylaxis: Patients receive cyclosporine IV on days -1 to 30 and then orally every 12 hours. Cyclosporine dose is then tapered beginning after day 50 and continuing for 6 months in the absence of GVHD. Once cyclosporine dose is significantly decreased, oral mycophenolate mofetil (MMF) is then administered twice a day. MMF dose is then tapered for 12 months in the absence of GVHD. Patients also receive methotrexate IV on days 1 and 3.
Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 33 patients would be accrued for this study within 2.1 years.
Eligibility Criteria
Inclusion Criteria:
One of the following cytologically proven myelodysplastic syndromes
Refractory anemia (RA)
RA with ringed sideroblasts
RA with excess blasts
Chronic myelomonocytic leukemia
International Prognosis Scoring System (IPSS) score of at least 0.5 OR red cell transfusion dependence for at least 6 months (2 units per month)
Patients with an IPSS score less than 0.5 may be eligible provided they previously had a higher IPSS score and received chemotherapy at that time
Suitable human leukocyte antigen (HLA)-matched donor (related or unrelated) available
No cord blood donors
Related donors must be genotypically matched (HLA A, B and DR) at 5/6 or 6/6 loci and may be a sibling, parent, or child
Unrelated donors must have high resolution typing done at A, B, C and DR, and must be matched at all or may have a single antigen or allele mismatch at no more than one of these loci
Patients must have < 20% blasts on bone marrow study within 1 month of study entry
Age of 18 to 70 years
Eastern Cooperative Oncology Group performance status 0-1
Life expectancy at least 6 months
At least 90 days since prior autologous bone marrow transplantation
Serum erythropoietin level greater than 100 for patients who have not received a prior course of epoetin alfa
No iron deficiency
Iron deficiency anemia treated with iron replacement therapy allowed
Bilirubin less than 2.0 mg/dL
Alkaline phosphatase less than 2 times upper limit of normal (ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 times ULN
Creatinine less than 2.0 mg/dL OR creatinine clearance greater than 50 mL/min
Left ventricular ejection fraction (LVEF) at least 45% by Multigated Acquisition scan (MUGA) or echocardiogram
Carbon Monoxide Diffusing Capacity (DLCO) at least 50% of predicted (corrected for hemoglobin)
Forced expiratory volume in 1 second (FEV_1) at least 50% of predicted
Recovered from prior chemotherapy
Physically and psychologically capable of undergoing study regimen
Able to receive 600 cGy of total body irradiation
HIV negative
Negative pregnancy test
Exclusion Criteria:
Pregnant or nursing
Having other medical condition that would reduce life expectancy
Active ongoing infection
Prior myeloablative or nonmyeloablative allogeneic transplantation for Myelodysplastic syndrome or acute myeloid leukemia
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 6 Locations for this study
Scottsdale Arizona, 85259, United States
Jacksonville Florida, 32224, United States
Boston Massachusetts, 02111, United States
Rochester Minnesota, 55905, United States
Cincinnati Ohio, 45236, United States
Philadelphia Pennsylvania, 19104, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.